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EFFECTS OF BRAIN REGION AND GENDER ON PROTON MAGNETIC RESONA NCE
SPECTROSCOPY IN NORMAL SUBJECTS.
Marlyanne M. Pol-Rodriguez and Robert K. Fulbright. Section of Neuroradiology, Department of
Diagnostic Radiology, Yale University School of Medicine, New Haven, CT.
The purpose of this study was to acquire spectra using proton magnetic resonance spectroscopy
(MRS) with a long echo time (TE) to measure clinically important brain metabolites in normal subjects. We
aimed to determine whether these metabolites vary across brain regions and between men and women. The
results of this study will constitute a normative database that will be used as a reference for MRS studies of
patients with neurological disease.
Single voxel proton (1 H) spectra were acquired in seventy-two subjects ranging in age from twenty
to forty-four years. Ten brain regions were examined. Six gray matter sites in the cerebrum included four
cortical areas in the frontal, parietal, tempora l, and occipital lobes, and two deep nuclear sites in the basal
ganglia and the thalamus. Two cortical white matter regions were in the parietal and the frontal lobes. Two
posterior fossa sites included the pons and the cerebellum. For each spectrum, the metabolites N-acetyl
aspartate (NAA), creatine (Cr) and choline (Ch) were identified. Ratios of NAA/Cr and Ch/Cr were
calculated for each brain region. A multifactorial analysis of variance was performed with the two
metabolic ratios as dependent variables and with brain region and gender as independent variables. Posthoc statistical analysis consisted of the Scheffé’s F statistic for significant difference between pairs of brain
regions for both metabolic ratios.
There was significant regional variation fo r both the NAA/Cr ratio (p < .0001) and the Ch/Cr ratio
(p < .0001). The NAA/Cr ratio was consistent within cortical gray and white matter but differed between
cortical gray (smaller ratio) and white matter (larger ratio). The Ch/Cr ratio was variable in the gray matter,
differed between some but not all gray and white matter regions, but was consistent within cortical white
matter regions. There was no difference between men and women for either metabolic ratio. These findings
provide the requisite normative values to use single voxel, long TE MRS in adult patients with neurological
disorders.
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1
INTRODUCTION
The phenomenon of nuclear magnetic resonance (MR) originates from the
interaction between atomic nuclei and an external magnetic field. The property of the
nucleus necessary for MR is the nuclear spin or spin angular momentum, which can be
described using both classical physics and quantum mechanics. The classical physics
approach explains the interaction between the external magnetic field and a nucleus that
has spin angular momentum. A quantum mechanical treatment is necessary to obtain
information about the interaction of electromagnetic waves and nuclear spins. The
quantum mechanical description dictates that the nuclear spin has quantized, discrete
values that depend on the specific nature of the nucleus. Nuclei with even atomic weights
and atomic numbers have a spin of zero (or no spin). Nuclei with an even atomic weight
and an odd atomic number have a whole number spin. Nuclei with odd atomic weights
have a half integer spin, the most common class seen in clinical spectroscopy (1). Most
nuclei studied in biological systems using MR techniques have a spin of ½. Due to the
low sensitivity of instrumentation, individual nuclei are not examined in the MR
experiment; instead, the entire collection of nuclei, or spins, inside a volume of interest is
treated as a unit because a larger entity is easiest to study. The number of nuclei present
per volume of tissue depends on the specific nucleus being examined.
If a tissue is placed inside a magnetic field, individual spins begin to rotate about
the magnetic field at a frequency proportional to the applied magnetic field and the
gyromagnetic ratio, which is characteristic for a specific nucleus. These nuclei will
distribute themselves between different energy levels depending on the spin quantum
number. The interaction of a spin with the external magnetic field produces a coupling
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between the spin and the magnetic field that causes the spin vector component parallel to
the magnetic field to begin to have discrete values. For a spin of ½, the only possible
values for such spin component are + ½ (parallel spin) and – ½ (antiparallel spin). The
parallel component is lowest in energy and the antiparallel component is highest in
energy. In the presence of a magnetic field, the tissue will have a slight excess of spins in
the lower energy state, compared to the higher energy state. In other words, the tissue will
be magnetized (1).
The difference in energy between two adjacent spin states is proportional to the
strength of the applied magnetic field. As the magnetic field strength increases, the
intensity of the MR signal increases because the energy separation between the spin
states increases, and because more nuclei in the lower energy state can now be excited to
the higher energy state (2). When an electromagnetic pulse equal to this energy difference
is applied to a magnetized tissue, a spin in the lower energy state will be excited to the
higher energy state. This process is called resonance absorption. Because there are more
spins in the lower energy state, the tissue will experience a net absorption of energy.
Following excitation with an electromagnetic pulse in the radiofrequency range, the spins
will reemit the absorbed energy at the same frequency and return to the lower energy
level through a process called relaxation (1).
The resonance phenomenon of MR is achieved by applying an oscillating
magnetic field (a radiofrequency pulse) perpendicular to the vector of the angular
momentum. The radiofrequency pulse (rf) has the same frequency as the Larmor
frequency. Following the excitation pulse, the spins are flipped into the horizontal, or xy
plane. The spins will then decay or return to their original equilibrium orientation. The
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proportion of magnetization that is perpendicular to the external magnetic field will
induce a voltage in a receiver coil. The voltage generated in the receiver coil is the MR
signal and is known as the free induction decay (1). The free induction decay is a time
domain signal that consists of the superposition of several signals that evolve at different
frequencies and decay with different time constants. This time domain signal is converted
from a function of time to a function of frequency using the Fourier transformation, and
the MR spectrum is produced. The spectrum is a display of absorption peaks occurring at
the various frequencies that contribute to the entire signal. The position, amplitude, and
width of each peak depend on the frequency, amplitude, and decay time of the
corresponding components. The integrated peak area is proportional to the number of
spins creating the signal. The peak position serves to identify the kind of spin examined,
and its distinct molecular environment.
Chemical compounds containing a particular nucleus can have slightly different
resona nce frequencies than those predicted for the nucleus alone due to the interactions of
the negatively charged electrons that surround the nucleus. Electrons have spin properties
similar to the protons and neutrons in the nucleus of the atom. When placed in an
externally applied magnetic field, electrons precess and generate a small magnetic field
around the nucleus. These local magnetic fields created by the electrons can add or
subtract strength from the external field. As a result, the nucleus experiences a slightly
altered magnetic field, and resonates at a slightly shifted frequency (2). This phenomenon
is called chemical shift and is one of the important properties of MR spectroscopy. The
chemical shift determines the resonance frequency position of each peak on a MR
spectrum. Chemical shift can be expressed as an absolute frequency, which is dependent
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on magnetic field strength. It can also be expressed as parts per million from the main
magnetic resonance frequency of the system used, which is independent of the strength of
the magnetic field (3).
Relaxation is another important concept in MR. Relaxation is described as the
process by which spins return to equilibrium after an initial perturbation (excitation).
Relaxation times differ between tissue types, and this difference is mainly responsible for
the contrast seen in conventional MR Images. Relaxation time measurements are
incorporated in the quantitative analysis of MR spectra to obtain tissue metabolite
concentrations and to gain insight into the molecular environments of spins. Relaxation
time differences between nuclei can also be used to selectively suppress signals to
simplify spectra. Two measures of relaxation are well defined, both of which describe
energy transfer by the excited spin. The relaxation time T1, known as the spin- lattice
relaxation time or longitudinal relaxation time, represents the restoration of the
longitudinal equilibrium. It is the time necessary for the z component of the
magnetization to return to 63% of its initial value after an excitation pulse (1). In clinical
MR spectroscopic (MRS) measurements, the magnetization achieves a steady state
because multiple radiofrequency pulses are applied repeatedly, and the time between
excitation pulses, TR, is almost never enough for complete return to equilibrium. In T1
relaxation, the energy absorbed after each pulse is transferred from the excited spin to its
surroundings. Most metabolites that are studied using MR spectroscopy have relatively
long T1 relaxation times, therefore, short TR times will result in significantly saturated
spins which makes quantification of signals difficult.
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T2 relaxation, also known as spin-spin relaxation or transverse relaxation,
represents the restoration of the transverse magnetization. It is the time it takes the
transverse component of the magnetization to decay to 37% of its original value. At
equilibrium (prior to excitation), the net magnetization is oriented along the z axis of the
applied magnetic field. After a 90° radiofrequency pulse, the longitudinal magnetization
disappears because the net magnetization rotates into the xy plane, so that at the end of
the pulse, the coherence or uniformity of the spins is in the transverse plane. Each spin is
synchronized and precesses at the same frequency such that a nearby spin of the same
kind will experience the same molecular environment and will easily absorb the energy
that is released. T2 relaxation refers to the energy relocation from an excited spin to a
nearby synchronized spin (1).
After energy absorption by the spins in a tissue, intermolecular and intramolecular
interactions, like vibrations or rotations, will cause the magnetic field around each spin to
fluctuate, inducing variations in their precessional frequency. This local field fluctuation
causes a gradual, irreversible loss of phase coherence as the spins exchange their energy
and the total transverse magnetization decreases. The modulation of the spin’s local
magnetic field due to vibrations and rotations is responsible for spin-spin relaxation. T2
relaxation can often be used to measure the restriction of molecular motion of a spin: the
longer the T2 relaxation, the more free or random the spin movement. With the passage
of time, the transverse coherence completely disappears and reforms in the longitudinal
direction through the process of T1 relaxation (1). Another reason for the loss of
transverse phase coherence is the inhomogeneity of the magnetic field. A spin always
experiences a fluctuating local magnetic field which causes changes in its precession
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frequency and lead to a loss in transverse phase coherence. When a dephased spin in the
transverse plane experiences a 180° radiofrequency pulse, it will in effect reverse its
phase relative to the resonant frequency, without changing its rate and direction of
precession. After a short delay of time, the spin will regain its transverse coherence.
Regaining of phase coherence induces a spin echo, a voltage in the receiver coil (1). Echo
time (TE) is the time between the excitation pulse and the 180° radiofrequency pulse in a
spin echo experiment.
Nuclei within a molecule can interact and affect the local magnetic field around
each other, an effect known as spin coupling. In a magnetic resonance spectroscopy
(MRS) measurement, the choice of echo time, TE, complicates the spectrum if the spins
under observation are coupled. Coupled spins preserve their frequency difference in spite
of any radiofrequency pulse or the static magnetic field. As a result, the phase modulation
of the signal is dependent on the time between radiofrequency pulses (1). Changing the
TE changes the type of info rmation that can be obtained. Using a short TE (< 30 ms)
allows observation of metabolites with short relaxation times along with metabolites that
show up at longer TE. The shortest possible TE produces the smallest losses secondary to
T2 relaxation and therefore the best signal-to-noise-ratio (SNR). Conversely, the
background signals from short T2 components are significantly larger at short TE, and
also, shorter and less specific radiofrequency pulses have to be used, potentially leading
to more signal contamination from outside the volume of interest (4). Short TE affects
not only the appearance of the peak, but also the intensities of the peaks because each
metabolite has its own relaxation time. Using long TE, only the signals from choline
(Ch), creatine (Cr), N-acetyl aspartate (NAA), and lactate are detected. The use of short
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TE, on the other hand, allows for identification of other metabolites like myoinositol,
glutamate, glutamine and glycine (3).
It is important to have the best possible magnetic field homogeneity over the
volume of interest for MRS analysis. Good field homogeneity allows the resolution of
resonances with frequencies that are close together. Most MR systems use a set of coils
known as shim coils to compensate for field distortions due to manufacturing
imperfections or environmental interference. Shimming is a procedure for optimizing the
field homogeneity, globally and locally, over the selected volume of interest. Uniform
magnetic field homogeneity leads to better spectral peak resolution and also decreases the
time required to obtain spectral information because of improved SNR (1;2).
The robust signal from the inherently high MR sensitivity of protons and the large
water content of biological tissue make clinical MR images possible. In MR
spectroscopy, however, the large water signal makes it very difficult to detect signals
from metabolites that have concentrations 10,000 to 100,000 times smaller than water.
Sensitivity is essential in clinical MRS, and measurement sequences must include ways
to suppress the prevalent water signal. Suppression does not have to be complete, but at
least a 50-100 fold reduction in the water peak amplitude is needed. Reduction of the
water signal by at least a factor of 1000 can be accomplished through a method know as
chemical shift selective excitation or CHESS, which uses low-power frequency selective
pulses to saturate the water proton resonance frequency and suppress the signal. The
residual water signal can be subtracted from the MR signal after data processing and
phase corrections (1-3).

8
In the clinical application of MR spectroscopy, selected localization techniques
allow the definition of small tissue volumes of interest, using anatomical MR images as
reference. Localization techniques may be characterized as single volume (or voxel) or
multivolume. In single voxel spectroscopy, a spectrum is obtained from a small volume
of tissue demarcated by the intersection of three orthogonal planes. There are three main
single voxel techniques, but only two of them are commonly employed clinically.
Stimulated echo acquisition mode (STEAM) and point resolved spectroscopy (PRESS)
techniques employ frequency selective radiofrequency pulses to excite the volume of
interest only. The image selective in vivo spectroscopy (ISIS) technique, which is not
commonly used clinically, employs generalized excitation and subsequent subtraction
(cancellation) of unwanted signals from surrounding tissue outside the volume of interest
(1). Both STEAM and PRESS are highly effective volume localization schemes, but there
are some major differences between them. The STEAM technique is better for
measurements involving short echo times (TE < 20 ms), and also achieves more
successful water signal suppression than PRESS, but the STEAM sequence looses signal
intensity by a factor of two and is highly susceptible to motion, multiple quantum effects
and diffusion processes. PRESS is the volume localization method of choice for long
echo times (TE > 135 ms). This sequence also has better signal intensity and is less
sensitive to patient motion and quantum effects (1;2).
Multiple voxel spectroscopy can be one-dimensional, two-dimensional, or threedimensional, and this technique is usually performed using chemical shift imaging (CSI).
CSI is a method that employs features of both conventional MR imaging and
spectroscopy. It is a technique for collecting in one measurement MR spectra from

9
multiple contiguous voxels covering a large region of interest. Data is obtained as
spectral maps and metabolite images, and these can be superimposed on conventional
MR images to compare changes in spectra from adjacent voxels, or to obtain the
distributional pattern of a particular metabolite within the tissue segment examined.
Although multiple measurements can be obtained at once using this technique, the SNR
for those values is much lower than that of single voxel measurements because good shim
and uniform water suppression is difficult to achieve over a large, heterogeneous volume
(1;2).
Magnetic Resonance Spectroscopy (MRS), a tool that has been used extensively
in research, has recently become a useful clinical technique to study the cellular and
molecular mechanisms of neuronal activity in the living brain. Proton MRS studies can
provide a non- invasive source of information for several brain compounds. In vivo MRS
studies of the brain can quantify the steady-state levels of neurochemicals, like glutamate
(Glu), N-acetyl aspartate (NAA) and γ-aminobutyric acid (GABA), which can be used as
markers for neuronal density and may reflect functional-synaptic properties, since they
are predominantly located within neurons (3;5;6). Other metabolites that can be measured
with proton MRS are choline (Ch), which is a chemical found in myelin and cell
membranes and is a marker of cell turnover and cell density; creatine and
phosphocreatine complex (Cr), markers of the energetic status of neurons; lactate, a
product of cell metabolism especially during anaerobic states; and glucose, glutamine,
lipids and myoinositol. The normal distribution of these chemicals in the brain has not
been studied extensively, but abnormal values have been observed in many neurological
diseases.

10
Long TE spectra (TE = 135 and 270 ms) obtained from proton MRS reveal the
major contributors to the proton signal to be NAA, Ch and Cr. The presence of NAA in
an MR spectrum can be attributed to its N-acetyl methyl group, which resonates at 2.02
ppm. Other less abundant N-acetyl groups also contribute to this peak. The exact role of
NAA in the brain is unknown, but it is believed to be a marker for neurons. NAA has
been shown to increase during brain development after birth and in childhood, and to
decrease with aging (1;7-10). A decrease in NAA concentration has been documented in
diseases involving neuronal and axonal loss, such as epilepsy, stroke, the majority of
dementias, hypoxia, encephalopathies, leukodystrophies, tumors, multiple sclerosis, and
other white matter diseases (3;6;11-18). Increased NAA is found in children with
Canavan’s disease, which is a genetic disorder where the enzyme that catabolizes NAA is
defective (10).
The peak for Ch occurs at 3.22 ppm. It arises from protons on methyl groups
attached to nitrogen in choline and other trimethyl ammonium compounds. Choline is a
component of the phospholipid metabolism of cell membranes and reflects membrane
turnover, and it is also a precursor for the synthesis of acetylcholine and
phosphatidylcholine (3). Increased choline probably suggests increased membrane
synthesis or breakdown, and can also indicate increased number of cells. The choline
peak in the brain arises primarily from phosphorylcholine and glycerophosphorylcholine.
Other compounds such as taurine and phosphoryl-ethanolamine also contribute to the
signal at 3.22 ppm. These compounds are particulary high in the immature brain.
Choline is the largest peak in normal spectra of neonate brain, and there is a decrease in
Ch concentration as the brain matures and develops (1;7;9;10). An increase in the Ch
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peak area in the adult brain is associated with Alzheimer’s disease, post- liver transplant,
primary and secondary brain tumors and epilepsy (1;6;13). A decrease in the Ch peak is
seen in hepatic encephalopathy and subacute and chronic cerebral infarction.
The peak for total Cr is seen at 3.03 ppm and it contains major contributions from
both creatine and phosphocreatine. Phosphocreatine (PCr) is thought to play a role in
sustaining energy-dependent systems in brain cells by functioning as a reservoir for highenergy phosphates and as a buffer in ATP and ADP stores. Cr can increase in
hypometablic states and trauma, and decrease in hypermetabolic states, hypoxia, stroke
and tumor. Cr has been considered stable enough, even in face of disease, to be used as
an intrinsic reference for reporting relative concentrations of other chemicals in the brain,
since it measures both Cr and PCr, which are maintained at equilibrium by creatine
kinase (1;3)
Lactate, if elevated, is also readily detectable using long TE spectroscopy and
appears as a doublet at 1.33 ppm. Lactate levels in the brain are normally low (less than 1
mM) such that it is usually not seen in the spectra of normal brain. The presence of
lactate typically indicates that non-oxidative carbohydrate catabolism is happening.
Lactate has been detected in patients with stroke, some brain tumors, hypoxia, anoxia,
mitochondrial encephalopathies, and in epileptic foci immediately after a seizure
(1;3;10;13;14).
Other metabolites that can be studied with MRS in vivo require short TE
sequences for visualization. The most prominent of these is myoinositol, a metabolite
involved in hormone-sensitive neuroreception when it is phosphorylated. Myoinositol
increases in Alzheimer’s disease and diabetes mellitus, and decreases in stroke, tumor
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and hypoxic encephalopathy. Other signals seen include: glutamine and glutamate;
glucose, which is elevated in spectra of diabetic patients; GABA, increased in epileptic
patients treated with vigabatrin; and lipid signals, seen in some tumors, stroke and acute
MS lesions (1;3).
Several studies have observe regional variations in normal brain metabolites
(5;19-21) as well as variations with age (7-9;22). Grachev et al. noted significantly
different metabolite concentrations between six regions of the brain, with the highest
concentration shifts for the nine metabolites measured happening in the prefrontal regions
(5). Michaelis et al. reported great heterogeneity of eight metabolites between brain
regions, and found highest NAA concentrations in pons and parietal gray matter, and
highest Ch concentrations in pons and cerebellum (19). Kreis et al. found NAA/Cr and
Ch/Cr ratios to be higher in parietal white matter when compared to gray matter spectra
(20). Komoroski et al. also observed significant regional differences in the major brain
metabolites when compared across regions of the brain, and reported a lower NAA/Cr in
the hippocampus, and lower NAA/Cr and Ch/Cr in basal ganglia (21). Regarding age,
earlier studies have shown that the dominant peak in short TE spectra of human brain
changes from being myoinositol in neonates, to Ch in older infants, to NAA in adults.
Some studies have shown that metabolite variations in adulthood are marked by
decreased NAA, Cr and Ch levels in older adults compared to young adults (23;24).
There is only a relatively small amount of data published addressing the effects of
gender on 1 H MRS in normal individuals, and the conclusions of these studies have been
conflicting. Charles et al., using the STEAM voxel technique (TE = 270 ms) with CSI,
saw no gender differences in NAA/Cr, NAA/Ch and Ch/Cr ratios in white matter, and
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cortical and noncortical gray matter (24). In contrast, Wilkinson et al., using a PRESS
sequence and TE = 135 ms, saw significantly smaller NAA/Ch and larger Ch/Cr ratios in
parieto-occipital white matter of males compared to females (25). Pouwels and Frahm
saw no gender differences using STEAM localization and TE = 20 ms to quantify
metabolite concentrations in several brain regions, except for a 1.3- fold higher
myoinositol level in parietal white matter of females. (26). Komoroski et al. again found
no difference between genders for the metabolite ratios measured in seven different
regions of the brain using STEAM sequence at TE = 30 ms (21). Most recently, Grachev
and Apkarian, also using STEAM at TE = 30 ms, demonstrated gender differences due to
increased levels of NAA in female sensorimotor cortex, and increased glucose in female
orbital frontal cortex (5).
No differences in metabolite concentrations have been reported between
equivalent locations in the right and left hemispheres of normal brain, but significant
differences in chemical concentrations, including NAA, Cr and myoinositol, have been
reported between white and gray matter (5;19-21). The proportion of gray and white
matter in a region of interest has the greatest effect on metabolite concentrations and
ratios.
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STATEMENT OF PURPOSE AND HYPOTHESIS
MRS techniques are very sensitive to minor changes in parameters, and therefore,
normal values must be established based on the methods used at each institution. This
study used the MRS techniques employed by the clinical MRI center at the Yale
University School of Medicine to measure thr ee different brain metabolites: NAA, Ch
and Cr. The ratios of NAA/Cr, and Ch/Cr were calculated in ten different brain regions
in normal adult males and females. Having normal values of these brain metabolites,
which can be used as a reference in the clinical application of MRS, will advance the
ability to use MRS to diagnose patients with neurological diseases.
We had three basic hypotheses for the age range of adults in our study: 1) The
NAA/Cr and Ch/Cr ratios would differ between gray matter and white matter regions, 2)
The NAA/Cr ratio would be consistent within gray matter and white matter, but the
Ch/Cr ratio would show more regional variability, and 3) Men and women would have
similar NAA/Cr and Ch/Cr ratios throughout the brain.
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METHODS
Seventy-two healthy subjects (32 men and 40 women) participated in this study.
Subjects ranged in age from 22 years old to 44 years. Mean age was 27 years (± 6 years).
Subjects were recruited from the university or medical center by word of mouth and
email. All subjects had attended college or were in college. Prior to entering the magnet,
subjects were provided with a description of the procedure, a consent form to read, and a
brief orientation to MR spectroscopy. Subjects filled out a questionnaire regarding past
medical and surgical history. All subjects gave written informed consent. Exclusion
criteria included claustrophobia, pregnancy, history of serious medical or neurological
illness and failure to fulfill the safety criteria developed by the Diagnostic Radiology
Department for patients undergoing MRI. The institutional review board approved this
study.
Magnetic resonance studies were performed on a GE Signa MRI system (General
Electric, Milwaukee, WI) at a magnetic field strength of 1.5 Tesla. Subjects lay supine in
the magnet with their heads immobilized by a neck support, foam wedges, and a
restraining band drawn around the forehead. Scout images in the sagittal plane were
acquired with parameters of 500/11 (TR/TE), a field of view of 24 cm, an imaging matrix
of 256 X 192, and 5- mm contiguous sections. Axial T2-weighted images were acquired
through the entire brain using a fast spin echo sequence with parameters of 3000/80
(TR/TE), a field of view of 22 cm, an imaging matrix of 256 x 192, an echo train length
of 16, and 3 mm contiguous sections. Based on the T2-weighted images, voxels in ten
regions of the brain were chosen for MRS spectra (see below). Voxels were 2 x 2 x 2 cm
or 2 x 2 x 1.5 cm in size. The spectra were acquired using a point-resolved 1 H
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spectroscopy (PRESS) technique, which is part of the fully automated Proton Brain
Exam-Single Voxel (PROBE-SV) software package supplied by General Electric
Medical Systems (GE Medical Systems, Milwaukee, WI). After the transmitter and
receiver were automatically adjusted, water signal was automatically shimmed to within a
line width of 3-5 Hz. The parameters for MRS were 2000/135 (TR/TE), a field of view of
22 x 22 cm, an imaging matrix of 256 x 192, total number of scans was 128, and scan
time was 4 min 56 sec. All data processing was performed by software provided by the
manufacturer. Spectral processing included zero- filling, Gaussian apodization, Fourier
transformation, water reference processing, frequency shift correction, and phase and
baseline correction. Using the curve-fitting software provide by the manufacturer, peak
integral values were determined. N-acetyl aspartate (NAA) was assigned at 2.02 ppm,
choline (Ch) at 3.2 ppm, and creatine (Cr) at 3.03 ppm. The peak areas of NAA, and Ch
were normalized with respect to Cr. The integral value of each peak was dimensionless
and represented relative measurement of the amount of each metabolite. The ratios
NAA/Cr and Ch/Cr were calculated. Spectra and integral values were displayed next to
an anatomic T2-weighted image on which a square box was overlaid to indicate the
anatomic location of each voxel from which the spectra was obtained.
In the exam time available, all ten brain regions could not be studied in each
subject, so spectra from three or four regions were sampled in three different subject
groups. In group 1, 22 subjects (10 men, 12 women) had spectra collected from the three
brain regions: the occipital lobe gray matter, which included aspects of the cuneus,
lingual gyrus and calcarine fissure, the lentiform nuclei (basal ganglia), and the posterior
white matter (primarily the parietal lobe). Group 2 consisted of 31 subjects (12 men, 19
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women) who had spectra collected from three brain regions: the frontal gray matter
(superior frontal gyri), the frontal white matter (bordering superior and middle frontal
gyri), and the pons. Fifteen of group 2 subjects also had spectra collected from the
temporal gray matter (primary auditory cortex in posterior aspect of the superior temporal
gyrus). In group 3, 20 subjects (10 men, 10 women) had spectra collected from three
brain regions: the thalamus, the cerebellum (hemisphere), and the parietal gray matter
(middle aspect of the intraparietal sulcus). Thirteen of group 3 subjects also had spectra
collected from the temporal gray matter as in group 2. Voxels in cerebral gray matter
regions were mainly gray matter (approximately 70%), but the inclusion of subcortical
white matter could not be avoided. Voxels in cerebral white matter regions were
primarily all white matter, with little or no inclusion of gray matter. Voxels in the
lentiform nuclei and thalamus contained small amounts of adjacent white matter tracts.
The pons consisted of both white matter tracts and brainstem gray matter nuclei. Voxels
in the cerebellum consisted of both gray and white matter. The midline, which includes
left and right hemispheric tissue, was examined for the frontal gray matter and the
occipital gray matter. The left hemisphere was examined for the seven other cerebral and
cerebellar regions. For the one brainstem region, the midline of the pons was studied.
Figures 1-4 illustrate the ten different brain regions and their corresponding spectra.
An ANOVA with age as the dependent variable and group as a factor
demonstrated no significant difference between the mean ages of the three subject groups
(F (2, 64) = .95, p = .4). The mean ages were 29, 27, and 27. An omnibus MANOVA was
performed that collapsed across the three groups and examined the two metabolite ratios
as the dependent measures and brain region (all ten regions) and gender as independent
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variables, or factors. Post- hoc analysis consisted of the Scheffé’s F statistic for any
significant difference between pairs of brain regions for both the NAA/Cr ratio and the
Ch/Cr ratio. To guard against the possibility that significant effects or interactions of
brain region and gender could result from differences in variance among the three groups
of subjects, a separate multifactorial analysis of variance (MANOVA) was performed for
each of the three subject groups with the metabolic ratios of NAA/Cr and Ch/Cr as the
dependent variables and with brain region and gender as factors. Post-hoc analysis again
consisted of the Scheffé’s F statistic for significant differences between pairs of brain
regions for both NAA/Cr and Ch/Cr.
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RESULTS
The omnibus MANOVA for the NAA/Cr ratio collapsed across the three groups
and ten brain regions revealed a main effect of brain region (F (9,213) = 27, p < .0001),
indicating regional variation for the NAA/Cr ratio. There was no main effect of gender (F
(1, 213) = 0.123, p = .73) and no interaction between brain region and gender (F (9, 213)
= .614, p = .78). Table 1 lists the mean NAA/Cr ratio and standard deviation for the ten
brain regions, collapsed across gender. The omnibus MANOVA for the Ch/Cr ratio
demonstrated a main effect of brain region (F (9, 213) = 85, p < .0001), again indicating
regional variation of Ch/Cr. There was no effect of gender (F (1, 213) = 1.26, p = .26),
and no interaction between brain region and gender (F (9, 213) = .742, p = .67). Table 2
shows the mean Ch/Cr ratio and standard deviation for the ten brain regions collapsed
across gender.
The main effect of brain region and lack of an effect of gender were confirmed
with the additional MANOVAs calculated separately for each of the three subject groups.
The MANOVA for Group 1 (basal ganglia, occipital gray matter and posterior white
matter) for the NAA/Cr ratio demonstrated a main effect of brain region (F (2, 56) = 30, p
< .0001) but no effect of gender (F (1, 56) = 2.384, p = .13) and no interaction between
brain region and gender (F (2, 56) = 0.87, p = .42). Results for the Ch/Cr ratio
demonstrated a main effect of brain region (F (2, 56) = 74, p < .0001) but no effect of
gender (F (1, 56) = 1.3, p = .25), and no interaction between brain region and gender (F
(2, 56) = .027, p = .97). The separate MANOVA for Group 2 (frontal gray matter, frontal
white matter, temporal gray matter and pons) for the NAA/Cr ratio demonstrated a main
effect of brain region (F (3, 90) = 25, p < .0001) but no effect of gender (F (1, 90) = .109,
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p = .74) and no interaction between brain region and gender (F (3, 90) = 0.165, p = .92).
Results for the Ch/Cr ratio demonstrated a main effect of brain region (F (2, 56) = 74, p <
.0001) but no effect of gender (F (1, 56) = 1.3, p = .25), and no interaction between brain
region and gender (F (2, 56) = .027, p = .97). The separate MANOVA for Group 3
(parietal gray matter, temporal gray matter, thalamus, and cerebellum) for the NAA/Cr
ratio demonstrated a main effect of brain region (F (3, 54) = 23, p < .0001) but no effect
of gender (F (1, 54) = .002, p = .96) and no interaction between brain region and gender
(F (3, 54) = 0.165, p = .25). Results for the Ch/Cr ratio demonstrated a main effect of
brain region (F (2, 56) = 74, p < .0001) but no effect of gender (F (1, 56) = 1.3, p = .25),
and no interaction between brain region and gender (F (2, 56) = .027, p = .97).
To determine which brain regions differed for a given metabolic ratio, the posthoc analysis consisted of calculating the Scheffé’s F statistic for pair-wise comparisons
between brain regions for the NAA/Cr ratio (Table 3) and the Ch/Cr ratio (Table 4),
respectively. Forty- five pair-wise comparisons were made for both metabolic ratios.
Twenty-one comparisons were significant for the NAA/Cr ratio (Table 3) and twentyeight comparisons were significant for the Ch/Cr ratio (Table 4). For the NAA/Cr ratio, a
direct comparison of regions containing predominately gray matter, like the four cerebral
cortical regions and the gray matter nuclei of the basal ganglia and thalamus, did not
show significant differences among each other. Similarly, a comparison of regions
containing predominately white matter, like the frontal white matter and the posterior
white matter, did not differ from each other. The white matter regions also did not differ
from the pons. Each cortical gray matter had a smaller ratio than each cerebral white
matter region and the pons. Each cortical gray matter region except the frontal area had a
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larger ratio than the cerebellum, with the frontal area not showing a significant difference
with the cerebellum. The NAA/Cr ratio of the basal ganglia was significantly smaller
than the frontal and posterior white matter regions and the pons, but was not significantly
different from the cerebellum. The thalamic NAA/Cr ratio, however, did not differ from
the cortical white matter regions or the pons, but was larger than the cerebellum.
The Ch/Cr ratio varied widely across different brain regions (Table 2 and Table
4). The cortical gray matter sites showed significant differences between each other, with
only the occipital gray and parietal gray matter regions having similar Ch/Cr ratios. The
ratio in the occipital gray matter was smaller than the ratio in the frontal and temporal
regions. The Ch/Cr ratios in the two cortical white matter sites were equivalent, but
unlike the NAA/Cr ratio, they had significantly different (smaller) ratios compared with
the pons. The basal ganglia and thalamus had statistically similar Ch/Cr ratios. The basal
ganglia showed few significant differences with other regions. The thalamus also differed
with only a few regions. The post-hoc analyses for both metabolic ratios resulting from
the MANOVA performed separately for each group yielded findings similar to the posthoc analyses from the omnibus MANOVA.
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DISCUSSION
The results reported in this study are generally consistent with those from earlier
studies, in terms of regional effects in brain metabolites (21;24;26). In this study,
significant differences in NAA/Cr were consistently observed between white matter and
gray matter. The regions of white matter had a larger NAA/Cr ratio compared with the
smaller ratios of the cortical gray matter, basal ganglia, and cerebellum. Other differences
in NAA/Cr ratios were also seen. The pons had a larger ratio than the gray matter, basal
ganglia and cerebellum. The cerebellum had a smaller ratio compared to the gray matter
and the thalamus. The NAA/Cr ratio did not vary within gray matter or within white
matter sites, as there were no significant differences in NAA/Cr when comparing the ratio
within gray matter regions and cortical nuclei, or within white matter regions and the
pons.
The Ch/Cr ratio demonstrated more regional variability than NAA/Cr, including
dissimilarity within gray matter sites (Table 2 and Table 4). Within predominantly white
matter sites, however, the Ch/Cr ratio did not differ significantly. The regional variability
in choline compounds has been noted previously (26). Other studies looking at regional
variations in brain metabolites have found differences between white and gray matter and
have even correlated this heterogeneity seen in vivo with in vitro findings, but for the
most part this has been done using actual quantification of metabolites (20;26). Most of
these studies, even those that used metabolite ratios (5;21), employed different
parameters of data acquisition than this study, hindering the ability to make in depth
comparisons between this study and previous ones. However, Marshall et al. measured
NAA, Ch, Cr, NAA/Ch and NAA/Cr in the right and left parie tal white matter of normal
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male and female volunteers using similar parameters as our study (PRESS sequence and
TE = 135 ms) (27). They reported mean NAA/Cr ratios (measured on consecutive days)
of 2.39 ± 0.39 and 2.41 ± 0.50 on right parietal white matter, and 2.55 ± 0.64, 2.34 ± 0.28
on left parietal white matter. These values are consistent with the mean NAA/Cr ratio in
posterior white matter observed in our study (2.419 ± 0.266).
The Ch/Cr ratio varied significantly within the gray matter locations compared in
our study. This variability could be technical in nature due to data collection and
processing limitations or errors. For example, the large voxel size inherent to single voxel
MRS means that volumes of interest do not contain only one tissue type. Nevertheless,
this variability could still be biological in nature since the same collection and processing
parameters were used to calculate NAA/Cr, and no variation was observed in those ratios
within gray and white matter sites. Our results, as well as others reported in the literature,
could be refined by segmenting gray and white matter to achieve a more homogeneous
volume of interest, and by off- line processing of data.
There were no significant effects of gender on either metabolite ratio across all
ten regions examined. This finding is consistent with prior studies which used STEAM
sequence and short TE in their evaluation of gender differences (21;24;26).
The methodology utilized in the acquisition and processing of data in this study
includes the same techniques employed at the clinical MRI center of the Yale University
School of Medicine. Some distinguishing features of the data in this study include the use
of single voxel PRESS technique employing a relatively large voxel size (6-8 cm3), a
long echo time (TE = 135 ms), and metabolite peak area ratio calculations instead of
absolute chemical concentrations. Single voxel spectroscopy with automated processing
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is widely available for clinical use because it is simple and easy to implement, achieves
excellent shim on small volumes, and produces a single spectrum that is immediately
accessible for interpretation. In comparison, multivoxel spectroscopy allows acquisition
of data from many locations at the same time and improves detection of regional
variability, but suffers from reduced SNR and more prominent sensitivity to differences
in susceptibility (1).
The voxel size used for spectra acquisition and the number of acquisitions are
directly proportional to the SNR. Reducing the voxel size requires an increase in the
number of acquisitions, and therefore the scanning time, in order to maintain the same
SNR (1). The large voxel size used in this study makes it more difficult to detect small
regional differences in spectra, but it allows for a better SNR in a shorter scanning time.
Voxel placement in certain locations, particularly the cerebellum, basal ganglia
and the pons in this study, can make it difficult to shim properly. These regions of interest
are close to the bones, which interfere with the shimming, affect the spectral quality and
therefore, the metabolite ratios obtained. Additional shimming procedures, off- line
processing and segmentation of gray and white matter improve ratio quantification of
metabolites, but clinical interpretation of spectra rarely uses these additional corrections.
Longer echo times, like the TE of 135 ms used in this study, offer the benefit of a
simpler spectrum with less peak interference from lipid signals, which facilitates the
interpretation of the spectrum. However, long TE MRS is less sensitive to metabolites
with short T2 whose variations may be important to the diagnosis of certain diseases.
PRESS localization is the sequence of choice for long TE spectroscopy because it
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provides a higher SNR and a lower sensitivity to motion compared to STEAM sequences
(1).
Quantification of metabolites in MRS can be difficult, so a more practical and
easier way to assess variations in metabolite levels is by calculating peak area ratios.
Metabolite ratios, like those calculated in this study using Cr as a reference, are favored
for clinical MRS because they are simple to obtain, require no technical expertise or
additional software, are not dependent on changes in coil loading or other differences
among individuals, and do not require relaxation-time measurements. Also, ratios are
unaffected by cerebral spinal fluid contamination because the metabolites of interest are
much lower in the CSF. The disadvantage of using metabolic ratios is that they are
sensitive to changes in the concentration of both metabolites in the ratio. Using Cr as a
reference in our study assumes that its concentration does not cha nge; however, this is
not always the case. Interpretation of NAA and Ch relative to Cr could result in a
misleading ratio.
Ideally, metabolite measurement of all ten regions of interest in our study would
have been obtained in each subject to facilitate the comparison of ratios across the brain
locations. Since only three or four regions were measured for each subject group in our
study, the main effect of brain region on the metabolic ratio could result from a difference
in variance between groups rather than a true difference between brain regions. To
account for this possibility, the Scheffé’s F statistic, the most conservative of the paired
comparison procedures, was used in the data analysis (28). This procedure is useful for
post-hoc comparisons if samples sizes vary in size and if there is a possibility of
heterogeneous variances amo ng groups. The post-hoc analyses resulted in similar
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findings in both the omnibus MANOVA and in the MANOVA calculated separately for
each group, suggesting that the three groups of subjects had relatively homogeneous
variance with regard to MRS measurements of the metabolic ratios.
Most databases of normal brain metabolites and ratios published to date use short
TE proton MRS. There is a need for a normative database based on single voxel MRS
acquired with a long TE. The database established in this study utilized such parameters,
and will be employed at our institution as a control in the clinical evaluation of patients
with proton MRS. The clinical applications of single voxel 1 H MRS range from the
detection and pre-operative evaluation of epileptic foci and the pre-operative evaluation
and post-treatment follow- up of tumors, to the detection of metabolic disorders,
especially inborn errors of metabolism and the evaluation of lesion load in multiple
sclerosis. Figures 5 and 6 illustrate examples of three clinical cases studied using MRS,
including abnormal spectra acquired from a metastasis in the frontal lobe and an
astrocytoma in the basal ganglia (Fig. 5), and an abnormal spectrum from a patient with a
metabolic disorder resulting in excess glycine (Fig. 6).
The effect of age was not evaluated in this study due to the small number of
younger children and older adults that have been studied thus far. The potential agedependent changes in metabolic ratios should be explored in future studies. Expanding
the age range of the current database would be beneficial to the clinical application of
MRS at our institution.
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FIGURES AND LEGENDS
Figure 1. Single voxe l PRESS proton MR spectra (TR/TE = 2000/135) from cerebral
gray matter locations, showing the choline (Ch), creatine (Cr), and N-acetyl aspartate
(NAA) peaks. Spin-echo MRI scans in the axial plane, used as an anatomic reference,
show the voxel location (left) of the acquired spectra (right). Locations include (A) the
frontal lobe of a male subject (voxel size = 2 x 2 x 2 cm); (B) the occipital lobe of a
female subject (voxel size = 2 x 2 x 1.5 cm); (C) the parietal lobe of a female subject
(voxel size = 2 x 2 x 1.5 cm); and (D) the temporal lobe of a female subject (voxel size =
2 x 2 x 1.5 cm). The chemical shift scale is in parts per million (ppm) relative to
tetramethylsilane.

Figure 2. Single voxel PRESS proton MR spectra (TR/TE = 2000/135) from cerebral
white matter locations, showing the choline (Ch), creatine (Cr), and N-acetyl aspartate
(NAA) peaks. Spin-echo MRI scans in the axial plane shows the voxel locations (left) for
the acquired spectra (right). Locations include (A) the frontal lobe white matter of a
female subject (voxel size = 2 x 2 x 1.5 cm); and the posterior white matter of a male
subject (voxel size = 2 x 2 x 2 cm). The chemical shift scale is in parts per million (ppm)
relative to tetramethylsilane.

Figure 3. Single voxel PRESS proton MR spectra (TR/TE = 2000/135), from (A) the
basal ganglia (voxel size = 2 x 2 x 2 cm) and (B) the thalamus (voxel size = 2 x 2 x 1.5
cm) of two female subjects, showing the choline (Ch), creatine (Cr), and N-acetyl
aspartate (NAA) peaks. A spin-echo MRI scan in the axial plane shows the voxel location
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(left) for the acquired spectrum (right). The chemical shift scale is in parts per million
(ppm) relative to tetramethylsilane.

Figure 4. Single voxel PRESS proton MR spectrum (TR/TE = 2000/135, voxel size = 2 x
2 x 1.5 cm) from (A) the pons and (B) cerebellum of two female subjects, showing the
choline (Ch), creatine (Cr), and N-acetyl aspartate (NAA) peaks. A spin-echo MRI scan
in the axial plane shows the voxel location (left) for the acquired spectrum (right). The
chemical shift scale is in parts per million (ppm) relative to tetramethylsilane.

Figure 5. Spin-echo MRI of the brain in the axial plane showing a frontal lobe metastatic
tumor (A) in a 59 year old female (left), and the corresponding MR spectrum (voxel size
= 2 x 2x 1.5 cm, right) showing a decreased NAA peak, and increased lipid signal.
Another example of the clinical use of MRS shows a basal ganglia astrocytoma (B) in the
axial plane (left), and an abnormal MR spectrum (TE = 135 ms, voxel size = 2 x 2 x 1.5
cm) with a decreased NAA peak, and an elevated Ch peak (right). The chemical shift
scale is in parts per million (ppm) relative to tetramethylsilane.

Figure 6. Single voxel PRESS proton MRS (TR/TE = 2000/135) showing normal peaks
for Ch, Cr and NAA (left), compared to the spectrum of a patient with non-ketotic
hyperglycinemia (right). An elevated glycine peak can be seen at a chemical shift of 3.56
ppm, to the left of the Ch peak. The chemical shift scale is in parts per million (ppm)
relative to tetramethylsilane.
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Figure 5A
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Figure 6
Normal MRS
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Table 1
Mean NAA/Cr Ratio in 10 Brain Regions

bg

20

Mea
n
1.834

occgm

22

2.000

.097

.021

powm

20

2.419

.266

.059

fgm

29

1.789

.210

.039

fwm

27

2.346

.370

.071

pgm

19

2.040

.199

.046

tgm

29

2.026

.192

.036

pons

28

2.427

.364

.069

Th

19

2.093

.228

.052

cb

20

1.512

.262

.059

Count

Std. Dev.
.336

Std. Err.
.075

bg = basal ganglia; occgm = occipital gray matter; powm = posterior
white matter; fgm = frontal gray matter; fwm = frontal white matter; pgm
= parietal gray matter; tgm = temporal gray matter; Th = thalamus; cb =
cerebellum

Table 2
Mean Ch/Cr Ratio in 10 Brain Regions

bg

20

Mea
n
1.018

occgm

22

.678

.075

.016

powm

20

1.242

.160

.036

fgm

29

1.144

.156

.029

fwm

27

1.459

.258

.050

pgm

19

.826

.125

.029

tgm

29

.929

.113

.021

pons

28

1.914

.302

.057

Th

19

1.133

.171

.039

cb

20

1.151

.144

.032

Count

Std. Dev.

Std. Err.

.192

.043

bg = basal ganglia; occgm = occipital gray matter; powm = posterior
white matter; fgm = frontal gray matter; fwm = frontal white matter; pgm
= parietal gray matter; tgm = temporal gray matter; Th = thalamus; cb =
cerebellum
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Scheffe for NAA/Cr
Ratio
Effect: Brain Region
Significance Level: 5 %

Table 3
bg, occgm
bg, powm
bg, fgm
bg, fwm
bg, pgm
bg, tgm
bg, pons
bg, Th
bg, cb
occgm, powm
occgm, fgm
occgm, fwm
occgm, pgm
occgm, tgm
occgm, pons
occgm, Th
occgm, cb
powm, fgm
powm, fwm
powm, pgm
powm, tgm
powm, pons
powm, Th
powm, cb
fgm, fwm
fgm, pgm
fgm, tgm
fgm, pons
fgm, Th
fgm, cb
fwm, pgm
fwm, tgm
fwm, pons
fwm, Th
fwm, cb
pgm, tgm
pgm, pons
pgm, Th
pgm, cb
tgm, pons
tgm, Th
tgm, cb
pons, Th
pons, cb
Th, cb

Mean Diff.
-.167
-.585
.044
-.512
-.206
-.192
-.593
-.260
.321
-.418
.211
-.345
-.040
-.025
-.426
-.093
.488
.629
.073
.379
.393
-.008
.325
.906
-.556
-.251
-.237
-.637
-.304
.277
.306
.320
-.081
.252
.833
.014
-.387
-.053
.528
-.401
-.067
.513
.334
.914
.581

Crit. Diff.
.348
.356
.327
.332
.361
.327
.330
.361
.356
.348
.318
.324
.353
.318
.321
.353
.348
.327
.332
.361
.327
.330
.361
.356
.301
.332
.296
.298
.332
.327
.337
.301
.304
.337
.332
.332
.335
.365
.361
.298
.332
.327
.335
.330
.361

P-Value
.9105
<.0001
>.9999
<.0001
.7707
.7407
<.0001
.4441
.1281
.0043
.5748
.0239
>.9999
>.9999
.0006
.9988
.0002
<.0001
.9997
.0294
.0044
>.9999
.1277
<.0001
<.0001
.3684
.2776
<.0001
.1146
.2007
.1230
.0255
.9986
.3807
<.0001
>.9999
.0080
>.9999
<.0001
.0005
.9999
<.0001
.0518
<.0001
<.0001

S
S

S

S
S

S
S
S
S
S

S
S

S

S

S
S
S
S
S
S
S

bg = basal ganglia; occgm = occipital gray matter; powm = posterior
white matter; fgm = frontal gray matter; fwm = frontal white matter;
pgm = parietal gray matter; tgm = temporal gray matter; Th =
thalamus; cb = cerebellum; S = significant
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Scheffe for Ch/Cr Ratio
Effect: Brain
Significance Level: 5 %
Region

Table 4
bg, occgm
bg, powm
bg, fgm
bg, fwm
bg, pgm
bg, tgm
bg, pons
bg, Th
bg, cb
occgm, powm
occgm, fgm
occgm, fwm
occgm, pgm
occgm, tgm
occgm, pons
occgm, Th
occgm, cb
powm, fgm
powm, fwm
powm, pgm
powm, tgm
powm, pons
powm, Th
powm, cb
fgm, fwm
fgm, pgm
fgm, tgm
fgm, pons
fgm, Th
fgm, cb
fwm, pgm
fwm, tgm
fwm, pons
fwm, Th
fwm, cb
pgm, tgm
pgm, pons
pgm, Th
pgm, cb
tgm, pons
tgm, Th
tgm, cb
pons, Th
pons, cb
Th, cb

Mean Diff.
.340
-.224
-.126
-.441
.192
.089
-.896
-.115
-.133
-.564
-.466
-.781
-.149
-.251
-1.236
-.455
-.474
.098
-.217
.416
.313
-.672
.109
.091
-.315
.318
.216
-.770
.012
-.007
.633
.530
-.455
.326
.307
-.102
-1.088
-.306
-.325
-.985
-.204
-.223
.781
.762
-.019

Crit. Diff.
.241
.246
.227
.230
.250
.227
.228
.250
.246
.241
.220
.224
.244
.220
.222
.244
.241
.227
.230
.250
.227
.228
.250
.246
.208
.230
.205
.207
.230
.227
.233
.208
.210
.233
.230
.230
.232
.253
.250
.207
.230
.227
.232
.228
.250

PValue
.0002
.1199
.7992
<.0001
.3400
.9743
<.0001
.9313
.8253
<.0001
<.0001
<.0001
.6968
.0099
<.0001
<.0001
<.0001
.9531
.0878
<.0001
.0003
<.0001
.9488
.9844
<.0001
.0003
.0281
<.0001
>.9999
>.9999
<.0001
<.0001
<.0001
.0002
.0006
.9436
<.0001
.0037
.0010
<.0001
.1447
.0591
<.0001
<.0001
>.9999

S

S

S

S
S
S
S
S
S
S

S
S
S

S
S
S
S

S
S
S
S
S
S
S
S
S

S
S

bg = basal ganglia; occgm = occipital gray matter; powm = posterior
white matter; fgm = frontal gray matter; fwm = frontal white matter;
pgm = parietal gray matter; tgm = temporal gray matter; Th =
thalamus; cb = cerebellum; S = significant
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